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Summary 
 
Inflammatory bowel disease (IBD) is a chronic condition 
that causes inflammation and swelling in the digestive 
tract. Although two types of IBD exist, Crohn’s disease 
(CD) and Ulcerative Colitis, this review will focus mainly 
on CD. The common pathology in IBD is the induction of 
interleukins and an abnormal Paneth cell phenotype. CD 
is caused by environmental and multigenic factors, 
including mutations in NOD2 and RUNX-3. NOD2 
promotes the induction of specific antimicrobial 
peptides that strengthen the immune system’s response 
against antigens. Mutations in NOD2 cause an 
overexpression of NF-kB activity and IL-1-β processing, 
which increases susceptibility to CD. Deletion of RUNX-
3 in mice induces colitis and causes an increase in 
certain interleukins. Moreover, IL-23R induces a pro-
inflammatory response while IL-11R promotes an anti-
inflammatory response. Defective autophagy has been 
linked to abnormal Paneth cells and an endotoxin-
induced inflammatory response in mice. The most 
promising CD treatments involve procedures that 
reduce inflammation by decreasing interleukin levels. 
Specifically, injection of anti-interleukin 12 antibodies, 
increasing the production of glucocorticoids through 
LRH-1, and the addition of polysaccharide A (PSA) can 
all serve as possible treatments for CD by down-
regulating the overactive immune system. Identifying 
more genes that increase susceptibility to CD can lead 
to novel treatments in the future.   
 
Introduction 
 
Inflammatory Bowel Disease (IBD) is a group of 
gastrointestinal disorders that causes inflammation in the 
intestines. The two main forms of IBD include Crohn’s 
disease (CD) and ulcerative colitis (UC). While CD can affect 
any part of the gastrointestinal tract, UC is restricted to the 
colon and the rectum. CD was named after an American 
gastroenterologist, Burill Crohn, in 1932, who reported 
having patients with severely inflamed ileums (Vermeire et 
al., 2007). In his report, Crohn specifically described patients 
experiencing painful symptoms, including abdominal pain, 
diarrhea, weight loss, and rectal bleeding (Baumgart and 
Carding, 2007). In addition, bloating, nausea, fatigue, and 
fever often accompany bowel pain (Hanauer, 2006). CD also 
leads to mechanical problems within the intestine, such as 
obstructions and abscesses. However, patients often 
experience long periods of remission in which symptoms are 
not present.  
 Approximately 500,000 people in the United 
States suffer from CD. The onset of CD usually occurs 
during early adolescence or late middle-age (Bouma and 
Strober, 2003).  However, the disease can occur at any age. 
Although CD equally affects men and women, people of 
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Eastern European descent and people from developed 
countries are more likely to be affected (Baumgart and 
Carding, 2007). Specifically, a group with a high incidence of 
CD is Ashkenazi Jews (Bouma and Strober, 2003). 
In patients with CD, the immune system is 
chronically activated even in the absence of antigens. This 
abnormal inflammatory response causes chronic 
inflammation and ulceration. The cause of CD is unknown 
(Bouma and Strober, 2003).  Environmental factors, such as 
smoking and genetic dispositions, can contribute to the 
pathology of the disease. Immediate relatives of patients 
with CD are more likely to develop the disease.  
CD can be diagnosed by performing a 
colonoscopy, which allows for the direct visualization of the 
colon. Also, biopsies and blood tests are often used to help 
diagnose the disease (Hanauer, 2006). Currently, there is no 
known cure for CD. However, anti-inflammatory drugs, such 
as corticosteroids, are often prescribed for treatment. Other 
medications, including immunosuppressants, can reduce the 
inflammation. By managing their stress, nutritional intake, 
and sleep patterns, CD patients can help reduce their 
symptoms (Baumgart and Carding, 2007).   
In CD, the inflammatory response mechanism is 
altered from the healthy pathway (Figure 1). There is an 
increase in pro-inflammatory cytokines observed in response 
to invading microbes. This immune response causes 
excessive inflammation. The immune system is unable to 
turn off, resulting in the symptoms seen in patients with CD 
(Fig 1). The specific factors that cause the increase in these 
proinflammatory chemicals are not well known. Also, the 
reason for the decreased ability of the immune system to 
destroy antigens remains unclear. 
 Past studies have demonstrated that CD has a 
strong genetic link. Previous genome searches for CD-
susceptibility genes have identified several loci, particularly 
in chromosome 16. (Satsangi, et. al., 1996) Recently, nine 
genes involved in the disease have been found, including 
NOD2, DLG5, IL23 receptor, ATG16L1, IRGM, and IL12B, 
NKX2-3, PTPN2, and NELL (Kaser, et. al. 2008). Even 
though researchers have identified genetic mutations that 
increase susceptibility to CD, the mechanism by which these 
genes operate and their specific link to inflammation requires 
further investigation. The exact role of different interleukins 
should also be examined.  
These gaps in knowledge are linked to the 
following hypothesis: mutations in certain genes, as well as 
defects in autophagy, can cause an increase in pro-
inflammatory stimulants and a decrease in bactericidal killing 
activity, resulting in excessive inflammation seen in people 
with CD. Looking at the genetic basis of CD can potentially 
lead to improved treatments, and eventually a cure. 
 
The Role of NOD2 in CD 
 
NOD2 Activates NF-κB and IL-1 β secretion  
Since CD patients have exhibit increased levels of the 
transcription factor NF-κB and a mutation in the NOD2 gene 
is increased, susceptibility to CD up to 40 times, the 
relationship between the gene and the nuclear factor needed 
to be investigated (Maeda et al., 2005). The NOD2 protein is 
active in a variety of immune system cells, including 
macrophages and dentritic cells, which protect the body 
against antigens. NOD2 is also active in epithelial cells, 
including Paneth cells found in the lining of the intestine. 
NOD2 is a pathogen-recognition molecule that detects 
muramyl dipeptide (MDP) in the intestine and triggers the 
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Figure 1: Model displaying a comparison between healthy and IBD immune system response  This figure depicts a comparison between a healthy and 
diseased inflammatory response to an antigen in the lamina propria. In the CD pathway, the levels of interleukins are significantly increased, and the 
bactericidal killing activity is decreased. The cause of these changes is unknown; however, this heightened pro-inflammatory response can result from 
specific gene mutations or deficiency in autophagy 
 
immune system to respond to an infection. This response 
occurs by the activation of NF-κB, which, in turn, regulates 
the activation of proinflammatory signaling pathways. The 
most common variation of NOD2, 3020insC, leads to the 
production of a slightly shorter NOD2 gene (Maeda et al., 
2005). However, there is a great deal of conflicting evidence 
in regards to NOD2 function and the role it has on the 
proinflammatory response. Some past researchers believed 
that the NOD2 variants were defective in activation of NF-κB, 
yet CD patients have exhibited increased levels of this 
nuclear factor (Maeda et al., 2005). In order to illuminate the 
mechanism by which NOD2 variants follow, cytosine was 
inserted into mice at position 2939 in the NOD2 locus, which 
corresponds to the 3020insC variant in humans (Maeda et 
al., 2005). The MDP stimulated Nod22939iC macrophages 
demonstrated increased NF-κB DNA binding activity 
compared to wild type (WT) cells (Maeda et al., 2005). When 
analyzing the expression of NF-κB target genes in terms of 
fold increase in mRNA expression, the results showed 
increased levels of a number of target genes, including IL-
1β, IL-6, and TNF-α (Maeda et al., 2005). However, only IL-
1β secretion was significantly increased in the Nod22939iC 
macrophages compared to WT controls (Figure 2A). When 
Nod22939iC mice were treated with dextran sodium sulfate 
(DSS) (a toxin involved in disrupting barrier wall function), 
there was an increase in apoptotic cells found in the lamina 
propria, which is linked to the activation of caspase-1 
(Maeda et al., 2005). This is an enzyme required for the 
secretion of IL-1β. In other words, a mutation in NOD2 
overexpresses IL-1 β by stimulating the activation of 
caspase-1. These results support the hypothesis that NOD2 
is necessary for the appropriate processing and release of 
IL-1 β. Thus, mutations in NOD2 increase susceptibility to 
CD by increasing NF-κB activation and IL-1 β secretion, 
which causes a heightened proinflammatory response 
typically seen in CD patients. 
 
 
NOD2 Activates hBD-2  
In order to fight invading microbes, epithelial cells induce 
antimicrobial peptides, such as human beta-defensin-2 
(hBD-2), as a defense response. Cytokines, such as IL-1, 
TNF-α, and IL-22, serve a role in activating hBD-2 (Voss et 
al., 2006). Since recent studies have shown an abundance 
of NOD2 in epithelial cells of the small intestine, among 
other regions, the relationship between NOD2 and hBD-2 
needed to be clarified.  Human embryonic kidney 293 cells 
(HEK293) that overexpress NOD2 were injected with both a 
hBD-2 promoter luciferase plasmid and with either a NOD2 
or NOD2 3020InsC expression vector. All samples were 
stimulated with MDP (Voss et al., 2006). Afterwards, the 
luciferase activity was measured, in order to analyze the 
hBD-2 promoter activity. The results showed significantly 
increased hBD-2 promoter activity for the NOD2 transfected 
cells upon MDP stimulation (Voss et al., 2006). To further 
verify that the activation of NOD2 by MDP mediates the 
secretion of hBD-2, a NOD2-specific siRNA was injected into 
primary keratinocytes to specifically inhibit NOD2 expression 
(Voss et al., 2006). Keratinocytes that were injected with 
NOD2 siRNA could not secrete hBD-2 when treated with 
MDP (Voss et al., 2006). These findings show that NOD2 
plays a vital role in protecting the cell against invading 
microbes by stimulating antimicrobial peptides. A mutated 
NOD2, on the other hand, is unable to produce the needed 
antimicrobial peptides and thus cannot destroy the antigen. 
This can result in an excessive proinflammatory response 
and lead to the symptoms of CD.  
The mechanism in which NOD2 activates hBD-2, 
which involves NF-κB and AP-1 sites, still needed to be 
investigated. To demonstrate the importance of binding sites 
for transcription factors NF-κB and AP-1 in the hBD-2 
promoter region, hBD-2 promoter luciferase expression 
constructs containing mutations of the two NF-κB sites as 
well as a mutated AP-1 site were used (Voss et al., 2006).  
 
 
 
 
 
The NOD2 overexpressing HEK293 cells were injected with 
this construct, treated with MDP, and analyzed for hBD-2 
promoter activity. The mutated sites caused a complete 
elimination of hBD-2 promoter activity. When only the two 
NF-κB sites were mutated, NOD2 induced hBD-2 promoter 
activity decreased almost completely, while with only the AP-
1 site mutation, hBD-2 promoter activity was decreased from 
7- to 5-fold (Voss et al., 2006). The role of NF-κB in the 
NOD2 mediated hBD-2 induction was confirmed by these 
findings, since they showed that mutating NF-κB sites 
resulted in much more severe effects.  These findings not 
only confirm the role that NOD2 plays in activating hBD-2, 
but also show the importance of the mediators involved in 
this pathway. Other studies have shown that CD patients 
have increased levels of NF-kB, but the actual form (mutated 
or not) of the transcription factor needs to be researched.   
 
Interleukin Function in IBD 
 
IBD has been characterized as a multi-gene disease. One 
gene associated with IBD disease that is of particular 
interest is Runx3. Runx3 is a transcription factor known to be 
linked to human autoimmunity, specifically involving in the 
regulation of TGF-b (transforming growth factor) and the 
development of helper T cells (Brenner, et. al., 2004). 
Successful deletion of Runx3 in mice induced colitis. A 
general increase in T lymphocytes and macrophages was 
also seen, indicating a heightened immune response 
(Brenner et al., 2004). Because Runx3 knockout mice 
developed colitis, a knockout of Runx3 is, therefore, linked to 
IBD. 
 Interestingly, Runx3 deletion was also associated 
with an increase in the expression of different interleukins. 
Interleukins are a group of cytokines synthesized by CD4+ T 
lymphocytes, monocytes, macrophages, and endothelial 
cells. Interleukins stimulate the immune response by 
promoting the differentiation and development of T cells, B 
cells, and hematopoietic cells (Brenner et al., 2004). Runx3 
knockout mice exhibited an increase in several interleukins, 
including IL-4, IL-5, and IL-12. An increase in the 
transcription factors T-bet and GATA-3 was also seen 
(Brenner et al., 2004). T-bet and GATA-3 both indirectly 
stimulate the development and differentiation of T cells 
through interleukins. An increase in the levels of several 
different interleukins further confirms a relationship between 
interleukin levels and IBD. 
 
IL23R As An IBD Gene 
Previous findings have shown that Runx3 deletion induced 
colitis and increased the levels of interleukin, which led to 
the investigation of specific genes controlling interleukin 
expression (Cheung et al., 2006). IL23R is a gene located on 
chromosome 1p31 that encodes a subunit of the 
proinflammatory cytokine interleukin-23 (Duerr et al., 2006). 
IL-23R has a specific role in promoting activation of T cells 
during an inflammatory response. Past studies of IL23R 
have demonstrated that the gene plays a significant role in 
inducing colitis. Moreover, many different IL23R variants are 
associated with the inflammation observed in patients with 
IBD (Murphy et al., 2003). 
A genome-wide association study of IL23R 
presented several SNPs, which caused both increased 
protection and increased susceptibility to Crohn’s disease 
(Duerr et al., 2006). The coding variant Arg381Gln was 
uncommon, with an allele frequency of 1.9% in Jewish 
individuals and 7.0% in non-Jewish individuals (Duerr et al., 
2006). The variant was shown to protect against the 
development of CD. In contrast, several different SNPs, 
including rs7517847, were found to be associated with 
increased susceptibility to IBD (Duerr et al., 2006). The 
discovery of these twofold genetic variants, that both 
contribute to the pathogenesis of IBD and serve as 
protection against the disease, allowing for a continuum of 
susceptibility, neutrality, and defensive effects of different 
genes (Duerr et al., 2006).     
 
Further Investigation of Interleukin Genes: IL-11R  
Interleukin 11 is a multifunctional cytokine that has been 
shown to exhibit protective effects on intestinal mucosa by 
significantly reducing the severity of colitis in animal models. 
IL-11 decreases the expression of many proinflammatory 
molecules, including IL-12 and IL-1b. However, IL-11 
expression is limited to colonic epithelial cells (Kiessling et 
al., 2003). IL-11 also triggers the activation of the Jak-STAT 
pathway, which regulates cell proliferation, differentiation, 
and apoptosis (Kiessling et al., 2003). Cells stimulated with 
IL-11 were found to contain higher levels of phosphorylated 
Jak (Kiessling et al., 2003). Stimulation of cells with IL-11 
also resulted in decreased levels of caspase-9, increased 
Akt anti-inflammatory effects, and overall increased cell 
survival (Kiessling et al., 2003). Due to these properties, IL-
11 therapy may be implemented as a possible treatment for 
IBD. Due to the cell proliferative effects of IL-11 in colonic 
epithelial cells, treatment using IL-11 should focus on the 
restorative effects of IL-11 phosphorylation, which results in 
diminished apoptosis (Kiessling et al., 2003). 
 
Role of Autophagy in CD 
 
Autophagy Background 
Autophagy is an evolutionarily conserved pathway that 
comes in several forms.  This review will particularly focus 
on macroautophagy, which will be referred to as autophagy 
(Kubella et al., 2008).  Autophagy plays an important role in 
cell and tissue homeostasis and has been linked to an 
assortment of human diseases (Cadwell et al., 2008). The 
process of autophagy involves encapsulating cellular 
contents into a double membrane vesicle, or an 
autophagosome, and delivering these contents to the 
lysosome, where they are degraded and recycled (Kubella et 
al., 2008). Autophagy is a protective mechanism that is 
upregulated at times of cellular stress, starvation, or growth 
factor withdrawal (Kubella et al., 2008). In particular, a 
process in autophagy called xenophagy is thought to protect 
the cell by eliminating or limiting the growth of bacterial 
pathogens (Kubella et al., 2008). Thus, autophagy is 
suggested to be involved in the regulation of the 
inflammatory response. 
 
Role of Atg16l1 in Mouse and Human Intestinal Paneth Cells 
The genome-wide association study identified a coding 
polymorphism in an autophagy gene, ATG16L1, as a risk 
factor for the development of CD (Cadwell et al., 2008).  
Atg16L1 is required for formation of a high molecular protein 
complex with the Atg12-Atg5 conjugate, which is required for 
autophagosomal formation (Saitoh et al., 2008). Moreover, 
Atg 5/Atg 16L1 regulates the rate of autophagy (Kubella et 
al., 2008). In addition, Atg16L1 defines where LC3 is 
conjugated to phosphatidylethanolamine (PE), which is 
crucial for autophagy, because PE recruits the Atg3-LC3 
intermediate to a source membrane of an autophagosome 
(Saitoh et al., 2008). Autophagosomes cannot function 
properly without these appropriate steps. A study performed 
by Cadwell et al.  (2008) showed that Atg16L1 deficient mice 
displayed abnormal Paneth cells. Paneth cells secrete 
granules of antimicrobial peptides and lysozyme (Yano et al., 
2009). These cells play a major role in the control of 
intestinal microbiota (Cadwell et al., 2008).  The 
abnormalities in Paneth cells included disorganized granules 
and a decrease in granule number (Cadwell et al., 2008). In 639	  
 
 
 
addition, there was a significant decrease in lysozyme. 
These results show that Atg16L1 is required for retaining the 
integrity of Paneth cell granule exocytosis pathways in mice.  
Similar abnormal phenotypes were seen in CD 
patients homozygous for the disease risk allele of ATG16L1 
(Cadwell et al., 2008). Furthermore, these Atg16L1 deficient 
mice displayed an increase in the expression of genes 
involved in regulating injury responses, including certain 
genes in the PPAR pathway (Cadwell et al., 2008). 
Interestingly, in patients with CD, there is a significant 
increase in transcription of genes involved in injury response 
maintenance, specifically adipocytokines leptin and 
adiponectin (Cadwell et al., 2008).  
These findings show an agreement between the 
abnormalities in Paneth cells from Atg16L1 deficient mice 
and the Paneth cells observed in CD patients with the risk 
allele ATG16L1. 
 
Loss of Atg16L1 Enhances IL-1β and IL-18 Production 
 Atg16L1 plays a major role in the control of the endotoxin-
induced inflammatory response. Mice that were deficient for 
Atg16L1, when exposed to LPS, had a significant increase in 
IL-1β and IL-18 (Saitoh et al., 2008). In previous studies, it 
has been shown that there is an irregular expression of 
inflammatory cytokines, such as IL-1β and IL-18, which were 
shown to be involved in the development of colitis (Saitoh et 
al., 2008). Mice that were deficient for Atg16L1, when 
treated with DSS, showed a significant decrease in survival 
and loss of body weight compared to WT mice (Saitoh et al., 
2008). Histological analyses performed on the colons of 
these mice revealed an increase in inflammation in Atg16L1 
deficient mice (Saitoh et al., 2008). In addition, there was a 
large area of ulceration and increased infiltration of 
lymphocytes seen in these mice (Saitoh et al., 2008). Also, 
the levels of IL-1β and IL-18 were elevated in the Atg16L1 
deficient mice compared to WT mice (Saitoh et al., 2008).  
The symptoms seen in DSS induced colitis are 
very similar to the symptoms of IBD patients.  These results 
show that Atg16L1 plays an important role in regulating the 
immune system response by controlling the production of IL-
1β and IL-18. These increased levels of specific 
inflammatory cytokines are associated with IBD.  
 
ATG16L1 Variant and Its Association With CD 
In humans, a coding polymorphism in the autophagy gene 
ATG16L1 variant was recently identified as a potential risk 
factor for the development of CD (Kubella et al., 2008). 
ATG16L1 encoding for threonine at amino acid 300 
(ATG16L1*T) provides protection to the cells; however, 
ATG16L1 carrying alanine instead of threonine 
(ATG16L*300A) causes increased susceptibility to CD 
(Kubella et al., 2008). Human gut epithelial cells Caco2 that 
have ATG16L1*300A when exposed to pathogens like 
Salmonella fail to rescue cells knocked out for ATG16L1 
(Kubella et al., 2008). However, the epithelial cells encoding 
for ATG16L*300T resulted in vigorous anti-Salmonella 
autophagy (Kubella et al., 2008).  
When representative confocal optical sections of 
infected ATG16L1-deficient and ATG16L1 allele-specific 
reconstituted Caco2 cells were observed, both of the 
variants were able to capture the pathogen within the 
autophagosome, yet the ATG16L1*300 captured the 
pathogen at a slower rate, showing that the variant has a 
reduced ability to regulate anti-bacterial autophagy (Kubella 
et al., 2008). These findings suggest that CD patients with 
the ATG16L1*300A allele, in comparison to patients with the 
ATG16L1*300T allele, will have an altered management of 
intracellular pathogens and internalized antigens (Kubella et 
al, 2008). Even though the results are significant for 
Salmonellae, Salmonella is not a causative agent of CD.  
Kubella et al. (2008) believe that cellular autophagy 
mechanisms for microbe recognition and degradation are the 
same for different intracellular pathogens. Hence, they 
hypothesized that in patients with the ATG16L1*300A allele, 
the homeostasis function of autophagy would work properly 
(Kubella et al., 2008). Nevertheless, these patients may 
have altered responses to bacterial components or infection 
in the gut because the gut microflora has increased 
exposure to antigens (Kubella et al., 2008).  Overall, these 
results do not suggest that the effect of the coding variation 
in ATG16L1 in humans would have a drastic effect.  
However, it would be interesting to observe the 
response of mice with the ATG16L1*300A allele to flagellin 
and TNF-α, IBD proinflammatory stimulants, since these 
mice would have an anti-bacterial autophagy that is 
mediated slower compared to mice carrying the 
ATG16L1*300T allele.   
 
Treatment 
 
Polysaccharide A 
Current research focuses on decreasing the proinflammatory 
response seen in both CD and UC patients by implementing 
treatments that lower levels of specific inflammatory agents. 
IL-17 is a cytokine involved in producing a pro-inflammatory 
response by overexpressing TNF-α and IL-6. B. fragilis, a 
comensal bacterium found in the gastrointestinal tract of 
animals, has been shown to suppress overproduction of IL-
17 with the addition of polysaccharide A (PSA) (Mazmanian 
et al., 2008). To study the use of PSA as a potential 
treatment for IBD, PSA was administered orally to DSS 
treated mice. These mice experienced a decrease in 
intestinal inflammation through the reduction of TNF-α and 
IL-6 (Mazmanian et al., 2008). Also, the mice did not 
experience any significant weight loss, which is one of the 
common symptoms seen in IBD patients. Interestingly, it was 
found that IL-10 is necessary for PSA function. DSS treated 
mice without IL-10 experienced an inflammatory response 
even with PSA treatment (Mazmanian et al., 2008). In the 
future, this treatment might have similar effects in lowering 
inflammation in the human gastrointestinal tract. Since B. 
fragilis is already present in the human tract and PSA may 
be administered orally, this type of therapy can be easily 
implemented in IBD patients  
(Mazmanian et al., 2008). Furthermore, the role of IL-10 to 
specifically treat CD needs to be further investigated.    
 
LRH-1 
As aforementioned, proinflammatory chemicals, such as IL-
1- β, IL-6, and TNF-α, are involved in inducing inflammation 
in intestinal epithelial cells during an inflammatory response. 
LRH-1, a liver receptor homolog, is able to decrease the 
levels of these cytokines by inducing the synthesis of 
glucocorticoids (Coste et al., 2007). Glucocorticoids serve to 
lower intestinal inflammation by both upregulating the 
expression of anti-inflammatory proteins and repressing 
proinflammatory proteins (Coste et al., 2007). Since IBD 
patients have been shown to exhibit a reduced expression of 
LRH-1, a mouse model was used to illuminate the 
relationship between LRH-1 and IBD. LRH-1 deficient mice 
exhibited reduced expression of glucocorticoids in epithelial 
cells. These results show that LRH-1 deficiency in the 
intestines predisposes mice to inflammation due to 
insufficient glucocorticoid production. Colon biopsies of 
patients with IBD, consistent with these findings, show 
decreased expression of LRH-1, along with other genes 
involved in glucocorticoid production (Coste et al., 2007). 
Furthermore, healthy sections of IBD sufferers’ colons 
showed increased levels of two enzymes: CYP11A1 and 
CYP11B1, which collectively produce glucocorticoids (Coste 649	  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Utilizing possible causes of IBD as potential treatment options (A) Stimulation of the mutant NOD2 gene by MDP causes overproduction of 
IL-1 β, which is associated with CD. (B) Administration of glucocorticoids into mice causes a decrease in the production of IL-1β and therefore serves 
as a viable treatment for CD. 
 
et al., 2007). These findings suggest that the LRH-1 pathway 
is involved in decreasing inflammation. The oral 
administration of glucocorticoids could be tested as a 
potential treatment for IBD.  
 
Anti-Interleukin-12 Antibodies 
CD is associated with overactive cytokine activity. IL-12 
(anti-interleukin-12) is a key cytokine that drives the 
inflammatory response by initiating helper T-cells. It is 
involved in regulating both the normal and abnormal 
inflammatory responses that are accompanied by 
autoimmune diseases, including CD. Since CD is 
characterized by an increased production of IL-12, the 
efficacy of implementing a human monoclonal antibody 
against IL-12 was studied as a possible treatment. CD 
patients were given seven weekly injections of either one or 
three milligrams of anti-interleukin-12 per kilogram of weight 
or placebo (Mannon et al., 2004). The results showed a 
decrease in IL-12, TNF-α, and interferon-γ secretion 
(Mannon et al., 2004). Most of the patients receiving anti-
interleukin-12 experienced significant clinical improvements. 
The treatment is, therefore, associated with decreased 
inflammatory cytokines at the site of the disease. 
Nevertheless, adverse effects, including diarrhea, 
dehydration, and abdominal pain, were seen in more than 
ten percent of the patients a short time after the study 
(Mannon et al., 2004). Thus, although all of the 
aforementioned treatments work to decrease the symptoms 
of IBD, a cure for the disease is yet to be discovered. 
 
Future Advances in CD Research 
 
CD has been shown to result from inappropriate regulation 
of homeostasis in intestinal mucosa in response to antigens. 
CD patients exhibit a malfunctioning gastrointestinal system, 
including excessive inflammation and painful symptoms. 
However, the cause of the malfunction remains poorly 
understood. Also, the exact role of interleukins and  
 
autophagy in the inflammatory response pathway was 
vaguely outlined. Based on the aforementioned findings, 
mutations in specific genes, including NOD2 and Runx3, 
suggest a potential cause for CD, due to the upregulation of 
certain inflammatory cytokines (Ogura et al., 2001). Specific 
interleukins, such as IL-11, decrease symptoms of CD and 
increase cell survival. However, other interleukins, such as 
IL-23, increase the likelihood of developing CD (Abraham et 
al., 2008). Overall, it has been shown that interleukins play a 
complex role in the inflammatory response in CD.  
Furthermore, ATG16L1 has been identified as a 
CD susceptibility gene and has been shown to play a role in 
the innate immune system response. The presence of this 
variant allele has been shown to cause defective autophagy, 
which results in decreased bactericidal activity and keeps 
the immune system from shutting down (Okazaki et al., 
2008). Although numerous genes have been identified as 
susceptibility factors for CD, the interaction and collective 
effect of these genes is unknown. Specifically, in the future, 
the interaction between NOD2 and ATG16L1 needs to be 
further investigated (Okazaki et al., 2008). The synergistic 
relationship between these genes may prove to be a 
significant contributor to the pathology of CD.  
 Since a mutation in NOD2 has been shown to 
overexpress NF-κB and stimulate the immune system 
response, decreasing levels of NF-κB may reduce the 
inflammatory response. This could serve as a potential 
treatment for CD patients. Also, since mutations in NOD2 
significantly increase IL-1β secretion, injecting an anti-
interleukin-1β antibody into CD patients may reduce 
symptoms (Figure 2B). In addition, it has been shown that 
injections of antibodies of IL-1β and IL-18 into DSS treated 
mice lower the severity of symptoms (Saitoh et al., 2008). 
Such injections can be tested on humans and incorporated 
into future treatments for CD.  Furthermore, identifying 
genetic loci that contribute to CD susceptibility can lead to 
the discovery of new genes that play a significant role in the 
development of CD (Parkes et al., 2007). Therefore, 
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treatment of CD would need to take into account the many 
different factors associated with the onset of this complex 
disease.  
 
Conclusion 
 
In Crohn’s disease, the immune response fails to be 
deactivated and contributes to the development of painful 
inflammation of the digestive tract. Many genetic factors, 
such as NOD2, Runx3, and ATG16L1, have been shown to 
increase susceptibility to CD. However, the specific 
interaction between these genes is unknown. The discovery 
of these genes and the role of inflammatory cytokines have 
led to the development of a prodigious number of 
treatments. Of these treatments, the targeting and 
suppression of inflammatory ILs leads to remarkable 
outcomes in patients suffering from CD. Patients who had 
previously been non-responsive to conventional treatments 
of steroids and glucocorticoids experienced profound results, 
where elimination of one IL resulted in a suppression of 
inflammatory cytokine cascades in the digestive tract, 
resulting in lowered inflammation of epithelial cells. These 
discoveries bring scientists increasingly closer to finding a 
cure for CD. 
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